Avenzo Therapeutics completes merger, gains $215M for oncology pipeline
Avenzo Therapeutics closed its merger on November 20, forming a Nasdaq-listed oncology biotech with ~$215M from a private placement, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The merger of Avenzo Therapeutics closed on November 20, creating an oncology biotech listed on Nasdaq, according to TradingView. The company reported roughly $215 million in proceeds from a private placement and expects its funding to last into late 2028.
Presentations of data from the combined pipeline are planned for the near term. Preliminary results for AVZO-1418 support the company's plan to expand globally.
why it matters
For markets, the deal is mostly a story about a smaller biotech strengthening its balance sheet. A funding runway into late 2028 gives the company time to reach its next milestones, and investors will watch whether the preliminary AVZO-1418 results hold up as expansion plans move forward.
tags
instruments
sources
- Avenzo Therapeutics: Merger launches a Nasdaq-listed oncology biotech with $215M in new capital — TradingView, 20 November 2026 at 21:49 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗